Ensign Peak Advisors’s Vor Biopharma VOR Stock Holding History

Ensign Peak Advisors’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-16,469	Closed	-$366K	–	1729
2024 Q4	$366K	Hold	16,469	–	–	﹤0.01%	1658
2024 Q3	$231K	Sell	16,469 -835	-5%	-$15.2K	﹤0.01%	1685
2024 Q2	$346K	Hold	17,304	–	–	﹤0.01%	1671
2024 Q1	$820K	Hold	17,304	–	–	﹤0.01%	1439
2023 Q4	$779K	Hold	17,304	–	–	﹤0.01%	1517
2023 Q3	$734K	Hold	17,304	–	–	﹤0.01%	1421
2023 Q2	$1.07M	Hold	17,304	–	–	﹤0.01%	1203
2023 Q1	$1.86M	Buy	17,304 +2,329	+16%	+$258K	﹤0.01%	876
2022 Q4	$1.99M	Buy	14,975 +4,500	+43%	+$445K	﹤0.01%	817
2022 Q3	$834K	Buy	+10,475	New	+$1.03M	﹤0.01%	1170
2022 Q2	–	Sell	-2,021	Closed	-$244K	–	2205
2022 Q1	$244K	Hold	2,021	–	–	﹤0.01%	1820
2021 Q4	$470K	Buy	+2,021	New	+$583K	﹤0.01%	1653

Other funds holding VOR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ensign Peak Advisors's VOR Position: Q1 2025 in Review

Ensign Peak Advisors sold out of Vor Biopharma (VOR) in Q1 2025, closing a stake of 16,469 shares — an estimated $366K sold.

Ensign Peak Advisors first reported a position in VOR in Q4 2021 and held it in 12 quarters. The position peaked at $1.99M in Q4 2022. 46 funds tracked by Wall St. Rank hold VOR as of Q1 2025.

Ensign Peak Advisors reported no remaining Vor Biopharma position as of Q1 2025 after selling out during the quarter.
Ensign Peak Advisors sold 16,469 Vor Biopharma shares in Q1 2025, an estimated $366K.
Ensign Peak Advisors first reported a position in Vor Biopharma in Q4 2021 and held it in 12 quarters.
Ensign Peak Advisors's Vor Biopharma position peaked at $1.99M in Q4 2022.
46 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2025.

Based on Ensign Peak Advisors's 13F filing for Q1 2025, filed 14 May 2025.